Premier Biomedical, Inc. (OTCMKTS:BIEI – Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 101,775 shares. Based on an average daily trading volume, of 26,682,366 shares, the short-interest ratio is presently 0.0 days.
Premier Biomedical Stock Down 14.3%
Shares of Premier Biomedical stock traded down $0.00 on Thursday, reaching $0.00. 600,112 shares of the stock were exchanged, compared to its average volume of 19,379,189. Premier Biomedical has a one year low of $0.00 and a one year high of $0.00.
About Premier Biomedical
Premier Biomedical, Inc is a biotechnology company focused on developing therapeutic products for conditions including pain, inflammation, cancer, and substance-use disorders. The company’s work has centered on proprietary formulations and drug-delivery approaches intended to provide alternatives to conventional treatments.
Premier Biomedical has historically operated as a development-stage business, emphasizing research, product formulation, and potential commercialization rather than maintaining a broad portfolio of established commercial products.
See Also
- Five stocks we like better than Premier Biomedical
- Synopsys Signals Confidence With $1B Accelerated Buyback, Analysts Raise Targets
- Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But Up
- Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?
- Failed Breakout in Tech? 3 Sectors Leading the Market Rotation
Receive News & Ratings for Premier Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premier Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
